Vertex Pharmaceuticals Incorporated (VRTX) Shares Sold by RPG Investment Advisory LLC

RPG Investment Advisory LLC decreased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,950 shares of the pharmaceutical company’s stock after selling 50 shares during the period. RPG Investment Advisory LLC’s holdings in Vertex Pharmaceuticals were worth $1,197,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Lombard Odier Asset Management Europe Ltd purchased a new stake in Vertex Pharmaceuticals during the third quarter valued at about $267,000. Dai Ichi Life Holdings Inc. increased its stake in Vertex Pharmaceuticals by 10.7% in the third quarter. Dai Ichi Life Holdings Inc. now owns 39,309 shares of the pharmaceutical company’s stock valued at $3,428,000 after buying an additional 3,799 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new stake in Vertex Pharmaceuticals during the third quarter valued at about $2,804,000. Baker Avenue Asset Management LP purchased a new stake in Vertex Pharmaceuticals during the third quarter valued at about $486,000. Finally, Capital World Investors increased its stake in Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock valued at $1,944,119,000 after buying an additional 599,586 shares in the last quarter. 94.38% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.73% during midday trading on Friday, hitting $123.14. 3,152,299 shares of the company were exchanged. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $130.69. The company has a market capitalization of $30.67 billion, a P/E ratio of 171.74 and a beta of 1.65. The company has a 50-day moving average of $120.30 and a 200 day moving average of $97.79.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.09. The business had revenue of $714.72 million during the quarter, compared to the consensus estimate of $692.64 million. Vertex Pharmaceuticals had a return on equity of 3.00% and a net margin of 8.64%. Vertex Pharmaceuticals’s revenue for the quarter was up 79.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.09 earnings per share. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post $1.66 earnings per share for the current fiscal year.

WARNING: This report was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/06/16/rpg-investment-advisory-llc-decreases-position-in-vertex-pharmaceuticals-incorporated-vrtx-updated-updated.html.

Several research firms recently issued reports on VRTX. CIBC raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $150.00 price objective for the company in a report on Friday, June 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $126.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, June 9th. TheStreet upgraded shares of Vertex Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Tuesday, May 2nd. Finally, Vetr upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and set a $119.50 target price for the company in a research note on Tuesday, May 30th. Nine investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $117.02.

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 7,500 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $130.00, for a total transaction of $975,000.00. Following the completion of the transaction, the executive vice president now owns 113,511 shares of the company’s stock, valued at $14,756,430. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey M. Leiden sold 147,101 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $129.50, for a total value of $19,049,579.50. Following the transaction, the chief executive officer now directly owns 312,142 shares of the company’s stock, valued at approximately $40,422,389. The disclosure for this sale can be found here. In the last ninety days, insiders sold 499,175 shares of company stock valued at $60,610,079. 1.90% of the stock is owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply